A Peptide Corresponding to GPIIb, 300-312, a Presumptive Fibrinogen ...

Vol. 267, No. 17, Issue of June 15, pp. 11729-11733,1992 Printed in U.S.A .

JOURNAL OF BIOLOGICAL CHEMISTRY (0 1992 hy The American Society for Biochemistry and Molecular Biology, Inc THE

A Peptide Corresponding to GPIIb,300-312, a Presumptive Fibrinogen y-Chain BindingSite on the Platelet Integrin GPIIb/IIIa, Inhibits the Adhesionof Platelets to at Least Four Adhesive Ligands* (Received for publication, March 17, 1992)

Donald B. Taylor$ and T. Kent Gartner From the Department of Biology, Memphis State University, Memphis, Tennessee38152

The platelet fibrinogen (Fg) receptor (GPIIbpIIa) is binding of Fn, Vn, and vWf to thisreceptor. This complexity an integrin which plays acritical role in hemostasis by exists because Fg contains a non-RGD-containing GPIIb/IIIa recognizing at least the four adhesive ligands: Fg, fi- recognition sequence (HHLGGAKQAGDV),which is present bronectin (Fn), vitronectin (Vn), and von Willebrand in the carboxyl terminus of the y-chain of Fg (22, 23). The factor (vWf). We reported that residues 309-312 of other GPIIb/IIIaligands, Fn, Vn, and vWf, have the common GPIIb, appear to comprise at least part of a Fg binding RGD sequence but lack the HHLGGAKQAGDV site. A synT. K., and Taylor, D. thetic peptide derivative of the y-chain recognition sequence site on the Fg receptor (Gartner, B. (1990) Thrornb. Res. 60,291-309). Here we report cross-links selectively to residues 294-314 of GPIIb (24). We that the peptide GPIIb, 300-312 (G13) inhibits plate- reported that a peptide with the sequence Gly-Ala-Pro-Leu let aggregation and binds Fg andVn. Significantly, this peptide inhibits the adhesion of stimulated plate- (GAPL) found as residues 309-312 in GPIIb appears to comprise at least part of a Fg binding site on GPIIb (25). In lets to Fg, Fn, Vn, and vWf, but not the adhesion of collaboration with Amrani and Kirschbaum (26-28), we reresting platelets toFn.Thus,GPIIb 300-312 may constitute a specific but common recognition site on cently demonstrated that GAPL-containing peptides inhibit GPIIb/IIIaforboth LGGAKQAGDV-and RGD-con- the binding of the Fg y-chain to platelets. To further characterize this platelet-specific LY subunit inplatelet function, a taining ligands. peptide corresponding to residues 300-312 of GPIIb (GDGRHDLLVGAPL (G13)) was synthesized. Because G13 is present in the region of GPIIb that was cross-linked by a In response to blood vessel injury, platelets mediate hemo- derivative of the y-chainof Fg, which is thought to represent stasis by adhering, spreading, and aggregating on exposed a unique recognition site for Fg, we were interested in deterextracellular matrix componentsof the damaged subendothe- mining if G13 could serve as a common recognition site for lium (1, 2). These cellular adhesion events are critical for the the binding of the other RGD adhesive ligands (which lack maintenance of normal vascular integrity. These platelet the HHLGGAKQAGDV sequence: Vn, vWf, andFn)to functions involve the recognition of large adhesive glycopro- GPIIb/IIIa. teins such as Fg,’ Fn, Vn, and vWf by the platelet integrin EXPERIMENTALPROCEDURES GPIIb/IIIa (3-7). Integrins are heterodimeric complexes conSynthetic peptides were synthesized, purified, and characterized as sisting of distinct a and /3 subunits which serve as cell surface previously described (25). The purified peak 1Fg and theinitial batch receptors for adhesive ligands (8-13). They participate in a of the EIIYPAGLV peptide were generous gifts from Dr. David wide variety of cellular functions including cell adhesion and Amrani, University of Wisconsin; the a-thrombin was provided by migration, development, hemostasis, the immune response, Dr. John Fenton 11, New York State Dept. of Health; the purified and wound healing (8-13). Many of the integrins recognize a vitronectin was kindly provided by Dr. Deane Mosher and Steve common amino acid sequence (RGD) as atleast part of their Bittorf, University of Wisconsin; the von Willebrand factor was minimum ligand recognition site (8).Synthetic peptides cor- generously donated by Dr. Zaverio Ruggeri, Scripps Research Clinic; responding to the individual RGDX sequences present in Fg, the thrombospondin was a generous gift of Dr. Dan Walz, Wayne State University; ADP, L-epinephrine, ovalbumin, and BSA (bovine Fn, Vn, and vWf each can inhibit theseligand/receptor inter- serum albumin) were from Sigma; collagen (calf skin, grade A) was actions (14-18). Consistent withthis ability, RGD-containing purchased from Calbiochem; sodium chromate (51Cr,250-500 mCi/ peptidescan interact directly with a& (aIIb = GPIIb; = mg Cr) was from Du Pont-New England Nuclear; t-butoxycarbonyl GPIIIa) (19-21). amino acids and Merrifield resins for solid-phase peptide synthesis The binding of Fg to GPIIb/IIIa is more complex than the were from Bachem Inc. (Torrance, CA) and Peninsula Labs (Belmont,

* This work wassupported by National Institutes of Health Grants HL42523 and HL46152. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. $Recipient of a VanVleet Foundation research fellowship. To whom correspondence should be addressed Dept. of Biology, Memphis State University, Memphis, TN 38152. Tel.: 901-678-2977; Fax: 901-678-3299. The abbreviations used are: Fg, fibrinogen; BSA, bovine serum albumin; Fn, fibronectin; Vn, vitronectin; vWf, von Willebrand factor; G13, the peptide GDGRHDLLVGAPL; L10, the peptide LGGAKQAGDV;PBS, phosphate-buffered saline.

CA). Platelet Aggregation-Whole blood obtained from aspirin-free human donors was drawn into acid citrate dextrose (39 mM citric acid, 75 mM sodium citrate, 135 mM glucose, pH 4.5). Washed platelets were prepared as previously described (25). Aggregation studies were performed at 37 ‘C using a single-channel aggregometer (Chrono-log Corp., Havertown, PA). Briefly, 0.1ml of a 1 X 109/ml platelet suspension was diluted with 0.35 ml of Ca2+-freeTyrode’s solution (1 g of glucose/liter, 8 g of NaCl/liter, 1 g of NaHCOa/liter, 0.2 g of KCl/liter, 0.1 g of MgC12.6H20/liter, 0.05 g of NaH2P04. H20/liter, pH 7.4) and theindicated amounts of peptides were added 30 s prior to initiation of aggregation by 0.05 units of thrombin. Dot Blot Assays-Briefly, purifiedpeak 1Fg (5 pg) orother proteins were applied to the center of nitrocellulose squares, allowed to dry,

11729

11730

GPIIb 300-312 Peptide Acts as Common Ligand Binding Site

and post-coated with 1%BSA for 1 h a t 37 "C.Blots were incubated with 100 pgof peptide/0.3 ml of PBS at 37 "C for 2 h. Blots were washed 3 times with blot buffer (PBS, 0.05% Tween 20, and 0.5% BSA) and subsequently incubated with purified monospecific antiG13 polyclonal Ig (5 pg/ml) or preimmune IgG (first antibody) for 90 min at ambient temperature. Following washes (3 times), the blots were incubated with a 1:lOOO goat anti-rabbit IgG horseradish peroxidase conjugate (second antibody) for 1 h. After washing, blots were developed using H202 and4-chloro-1-naphthol. Rabbits were immunized with GI3 derivatized to keyhole limpet hemocyanin (Sigma) according to a previously reported immunization protocol (29). Antiserum raised against GI3 was preadsorbed against nonderivatized Sepharose 4B and precipitated with 40% (NH4)2S04,and IgGs were isolated by affinity chromatography using a protein G column (Boehringer Mannheim). Anti-G13 IgG fractions were made monospecific by affinity chromatography with a GDGRHDLLVGAPL-Sepharose 4B column. IgGs were isolated from preimmune sera obtained from the same rabbit prior to immunization with the G13. Platelet Adhesion Assays to Fg-The platelet adhesion assays were performed as previously described (25, 31). Chromium labeled platelets were stimulated sequentially with epinephrine (5 p ~ for) 5 min and then with ADP (30 p ~ for) 5 min prior to use (25,31). Adhesion was allowed to proceed for 30 min prior to termination of the assay. Two types of controls were used as indicators of nonspecific binding in these assays: 1) platelet adhesion was measured on BSA-coated wells, and 2) platelets were incubated a t 37 "C a t pH 7.8 in the presence of 5 mM EDTA for 15 min to irreversibly inactivate GPIIb/ IIIa complexes thereby minimizing adhesion to Fg mediated by its receptor (25). Typically 5-8% of the platelets in the platelet suspension adhered. Platelet Adhesion to Fn, Vn, and uWf-Platelet adhesion assays were performed as described (25,31) with the followingmodifications. Fn and Vn were dissolved in 0.1 ml of adhesion solution (25) at a final concentration of 5 pg/ml and incubated in wells of Immulon-1 microtiter plates (Dynatech) overnight at 4 "C. vWf was dissolved in 0.05 ml of adhesion solution a t a final concentration of 10 pg/ml. For assays of platelet adhesion to Fn and Vn, labeled platelets were stimulated, first with epinephrine (5 pM for Vn, 20 pM for Fn) for 5 min and then with ADP (30 p ~ for) 5 min, prior to use (25). For assays of platelet adhesion to vWf, platelets were stimulated with cythrombin (1.0 unit/ml). Adhesion was allowedto proceed for 30 min except for the Vn experiments, which were allowed to proceed for 60 min prior to termination of the assays. Adhesion of stimulated platelets to all three ligands was saturable and could be inhibited with GRGDSP or LGGAKQAGDV peptides and by 5 mM EDTA. Adhesion of Resting Platelets to Fn-Assays of adhesion of stimulated platelelets to Fn were performed as described previously. Experiments for adhesion of resting platelets to Fn were performed exactly as described (33) except the platelets were allowedto incubate in the Fn-coated wells for 45 min instead of 30 prior to aspiration. Fn was purified essentially as reported (33). Briefly, fibronectin was isolated from fresh human citrated plasma (pH 6.4)by affinity chromatography on gelatin-Sepharose (Pharmacia). Plasma (100-150 ml) was applied to the column (50-ml beads) which had been equilibrated with 0.05 M Tris-HC1 buffer (pH 7.6), 0.15 M NaCl, 0.025 M caminocaproic acid. After all of the plasma had entered the beads, the column was washed extensively with equilibration buffer until the absorbance reached baseline. Prior to elution of bound fibronectin, the column was washed sequentially with 1 M NaCl and 1 M arginine in equilibration buffer (50 ml each). Fibronectin was eluted with 1 M NaBr in 0.05 Tris-HCI, 0.025 M c-aminocaproic acid (pH 5.3). The protein-containing fractions werepooled and extensively dialyzed against 0.039 M Tris/phosphate buffer, pH 8.6, and concentrated via ultrafiltration. The isolated fibronectin yielded a single band on sodium dodecyl sulfate-polyacrylamide gels under nonreducing conditions and twoclosely spaced bands ofhigh molecular weight (215,000-230,000)under reducing conditions.

RESULTS

Platelet Aggregation-The G13 peptide was initially characterized as aninhibitor of platelet function. G13 was a potent inhibitor of platelet aggregation compared with a scrambled control peptide (EIIYPAGLV) (Fig. lA). An analogue with the conservative substitution G302to A302 was synthesized to demonstrate that theeffect of G13 was not due to thepresence of an inverted RGD at the amino terminus of the peptide.

A

B

1

2

3

4

5

FIG. 1. A, inhibition of platelet aggregation by peptides. Washed platelets (1 X IO*/assay)in Tyrode's buffer (pH 7.4) were stimulated with a low dose of cy-thrombin (0.05 units/assay) in the presence and absence of peptide. Traces a-c correspond to aggregation in the presence oE GPIIb, 300-312 (GDGRHDLLVGAPL),GDARHDLLVGAPL, and scrambled control peptide (EIIYPAGLV), respectively. Peptides were tested at a final concentration of 500 p ~ B,. a nitrocellulose dot blot assay was used to demonstrate binding of G13 to immobilized fibrinogen. Blot 1 represents binding of immobilized Fg to GI3in the fluid phase. The controls demonstrate that thebinding of G13 to Fg is specific. When BSA was substituted for Fg, G13 did not bind (blot 3). Neither of the first antibodies (preimmune or antiG13) bound to Fg- or BSA-blockedsites (blots 2 and 4, respectively). The second antibodies (goat anti-rabbit IgG-horseradish peroxidase) also failed to recognize Fgor BSA (blot 5).

The rationale for the design of this peptide was that RADcontaining peptides are much less potent thanRGD-containing peptides as inhibitors of Fg binding to platelets (30). This analogue retained activity in assays of platelet aggregation but in general was slightly less potent thanG13; however, the substitution did not result in significant a loss of activity (Fig. IA).These results are consistent with an earlier study demonstrating that peptides containing inverted RGD sequences inhibited neither the adhesion of thrombin-stimulated platelets to Fg, Fn, or vWf, nor the binding of lZ5I-Fnto platelets (16). Also the peptide VDGRS lacks inhibitory activity in assays of platelet aggregation? G13 Binds Fg and Inhibits Fg Binding-One explanation for the inhibition of platelet aggregation by G13 is that the peptide behaves as a receptor mimic and thereby inhibited the binding of Fg to platelets. G13, but not a control peptide (GPIIb,829-837), inhibited Fg binding to GPIk1/111a.~Using a modified enzyme-linked immunosorbent assay, we previously demonstrated that an analogue of the GAPL peptide directly bound Fg in a specific and saturable manner (25). Polyclonal anti-G13 IgG demonstrated the direct binding of G13 to immobilized Fg (Fig. 1B). G13 Inhibits Platelet Adhesion toFg-The physiological relevance of the ability of G13 to bind Fg was tested by assaying G13 for the ability to inhibit the adhesion of epinephrine/ADP-stimulated platelets to Fg (25). G13, but not a control peptide, was a potent inhibitor of platelet adhesion to Fg (Fig. 2). The level of inhibition was a function of the concentration of peptide used in the assay (ICsovalue of 350D. B. Taylor and T. K. Gartner, unpublished observations. D. Cheresh, personal communication.

GPIIb 300-312 Peptide Acts

as Common Ligand Binding Site A.

m

11731

"WI

0 Fn

O l 0.0

.

" b

GPllb300-312

-t

CTRL

,

0.5

.

, 1.o

.

, 1.5

.

\ 2.0

clrl

EDTA GRGDSP

L10

G13

9c1

'llb

VnR

Peptide [mM] FIG.2. Dose-response curve demonstrating the inhibition of platelet adhesion to Fg by G13. Data are reported as total binding with nonspecific binding usually representing less than 12% of total binding. The control peptide (EIIYPAGLV) contains ascrambled GAPL sequence. The results presented are means of 10 separate experiments (data points represent a t least quadruplicate determinations). Error bars represent the range of the data. 400 pM) (Fig. 2). As little as 50 p~ gave 15% inhibition and 1.5 mM abolished adhesion to the extentof background ( n = 10 separate donors). G13 Inhibits the Adhesion of Platelets to Multiple LigandsNext it was determined whether G13 behaves as a common recognition site for the binding of the otheradhesive ligands (Vn, vWf, and Fn) toGPIIb/IIIa, or as a unique recognition site for Fg. In other words, can this peptide affect the functions of RGD containing ligands which lack the HHLGGAKQAGDV sequence? This question was addressed by including peptide in platelet adhesion assays with various ligands (Fig. 3A). Stimulated platelets attached in a timedependent and saturable manner to all of the ligands tested but did not bind to BSA. Between 6 and 7% of the platelet suspension (-6-7 x lo5cells) adhered to each of the ligands, and theadhesion of platelets to all of the ligands was inhibited by the synthetic peptides GRGDSP and LGGAKQAGDV (L10). The adhesion of stimulated platelets to these ligands was also inhibited by 5 mM EDTA. Surprisingly, G13 inhibited adhesion of platelets to all the ligands while a control scrambled peptide (Fig. 3, scr) had little effect at the same concentration. A different GPIIb peptide (designated *I%), corresponding to residues 829-837 (located in theextracellular portion of the molecule, but outside of the region of GPIIb 294-314), was synthesized and tested for its effect on adhesion of platelets to Vn, vWf, and Fn. The peptide *IIb (1.5 mM) had little effect on theadhesion of stimulated platelets to Fn or vWf and only a marginal effect on adhesion to Vn (29% inhibition.) Also, a peptide similar to G13 from the homologous region (residues 317-330) (59) of the a subunit of the Vn receptor (GDDYADVFIGAPL)was inactive as an inhibitor of platelet adhesion to Fn and vWf (1.5 mM).This peptide was a partial inhibitorof the adhesion to Vn (29% inhibition). At a final concentration of 1.5 mM, G13 inhibited the adhesion of stimulated platelets to vWf by 80% with an apparentICso value of 750 p~ ( n = 5 donors), while inhibiting adhesion to both Vn and Fn by -68% ( n = 4 donors each). The calculated ICs0 values for the inhibition of platelet adhesion to Vn and Fn are 532 and 682 p ~ respectively , (Fig. 4).As a control to ensure that G13 is not a nonspecific inhibitor of general platelet-platelet interactions, the peptide was tested for the ability to inhibit ristocetin-mediated agglutination of platelets (32) in platelet-rich plasma. The G13 peptide had no effect (data not shown). G13 Binds to an RGD-containing Ligand Which Lacks the HHLGGAKQAGDV Sequence-To determine the mechanism by which G13 inhibited the adhesion of stimulated platelets

1

2

3

4

5

6

FIG.3. A, inhibition of platelet adhesion to Fn, Vn, and vWf by a peptide analogue of GPIIb- 300-312 (G13). The percentage of platelets adhered to substrate-coated wells is indicated on the ordinate. The bar labeled ctrl represents the adhesion of stimulated platelets to theindicated substrate ( i e . Fn,Vn, vWf, and BSA) in the absence of peptide. The bar labeled C13 corresponds to theextent of adhesion in the presence of a peptide analogue of GPIIb, 300-312. The bar labeled scr corresponds to the extent of adhesion in the presence of the scrambled control peptide (EIIYPAGLV). The bar labeled VnR corresponds to the extent of adhesion in the presence of a peptide analogue of residues 317-330 of the VnR a subunit. The bar labeled *IIb represents adhesion in the presence of a peptide corresponding to GPIIbm829-837. All peptides were tested at a final concentration of 1.5 mM. The results presented are means of a t least four separate experiments (data points represent a minimum of quadruplicate determinations). Error bars indicate standard deviation of the data. B , G13 binds to immobilized Vn but not immobilized collagen,thrombin, casein, ovalbumin, or thrombospondin. Nitrocellulose dot blot assays were performed exactly as detailed under "Experimental Procedures." Blot 1 represents binding of Vn to G13 in the fluid phase. Blots 2-6 represent the absence of any significant binding of G13 to thrombospondin, collagen, thrombin, casein, and ovalbumin, respectively.

"WI

Fn

Vn

FIG.4. Dose-response data demonstrating the inhibition of platelet adhesion to vWf, Fn, and Vn as a function ofthe concentration of G13. Data are reported as percent platelet adhesion on the y-axis andtest ligand on the x-axis. Final peptide concentrations were as follows: (control; o), f?d (0.5mM), 0 (0.75 mM), €4 (1.0 mM), 0 (1.5 mM). The results presented represent the means of the pooled data with each concentration point for a particular ligand representing a minimum of eight replicate determinations. Error bars correspond to thestandard deviation of the data.

to RGD-containing ligands which lack the HHLGGAKQAGDV sequence, we performed direct binding studies of G13 to Vn and Fn. As was the case for Fg (Fig. lB), G13 bound to immobilized Vn in adot blot assay using anti-G13 antibodies (Fig. 3B). Thebinding was specific since G13 didnot bind to collagen, thrombin, casein, or ovalbumin, and only a slight amount of binding to thrombospondin could be detected in this system. Using the dot blot assay, we were unable to discern whether G13 bound directly to immobilized Fn due to

GPIIb 300-312 Peptide Acts

11732

as Common Ligand Binding Site

the binding of all of our antibodies to Fn. Effect of GI3 on Adhesion of Resting Platelets to FnInterestingly, at concentrations exceeding the ICso value for inhibition of adhesion of stimulated platelets to Fn, G13 had no effect on the adhesion of resting platelets to Fn (Fig. 5). G13 was included in assays of resting plateletsto Fnsince an RGDS-sensitive platelet integrin (Ic/IIa), distinct from GPIIb/IIIa, functionsas a receptor for the adhesion ofresting platelets to immobilized Fn (33). Even though G13 had no effect on the adhesion of resting plateletsto Fn, this adhesion was inhibited by 1 mM GRGDSP (data not shown). These results are consistentwith earlier studieswhich demonstrated that GRGDSP at 1 mM could inhibit the adhesion of resting platelets to Fn (33) and also demonstrate that G13 cannot inhibit thefunction of all RGD-sensitive integrins.

GPIIb (designated B12) was implicated in Fg binding (36). Direct comparisons between the two peptides, 296-306 (generously supplied by Dr. Edward Plow, Scripps Research Clinic) and 300-312, revealed that they have similar potencies as inhibitors of the adhesion of stimulated platelets to Fg ( n = 3, data not shown). The inhibition of ligand attachment by these two peptides might be explained by the presence of the overlapping sequence (300-306) shared by B12 and G13. However, the presence of this overlapping stretch cannot solely account for the inhibition byG13, since a peptide lacking GAPL (300-308) is notaspotentan inhibitor of platelet aggregation or platelet adhesion as G13.' Therefore, it appears that the GAPL moiety contributes to the function of G13. It also appears then that this entire conserved region of GPIIb (294-314) is important in ligand recognition. Recently, a distinct region in GPIIb (658-667) has been hypothDISCUSSION esized to play a role in ligand binding (37). A variety of studies have implicated a number of regions as Thedata described here implicate. residues 300-312of GPIIb in adhesive ligand binding to GPIIb/IIIa, but not to ligand binding domains of GPIIIa. Cross-linking studies with GPIc-IIa. G13 bound to immobilized Fg and Vn and inhibited an RGD peptide implicated residues 109-171 of GPIIIa as a platelet aggregation and Fg binding to GPIIb/IIIa. The pep- recognition site within the @-subunitof the Fg receptor (21, tide, but not a scrambled control, inhibited the adhesion of 38). These results were supported by studies of GPIIb/IIIa epinephrine/ADP-stimulated platelets to Fg in a dose-de- from two patients who express the CAM variant of Glanzpendent manner. G13 also inhibited the adhesion of stimu- mann's thrombasthenia. The GPIIIa molecules of these two lated platelets to Fn, Vn, and vWf, while a peptide found in patients have a single amino acid substitution (Asp"' to the homologous region of the a subunit of the Vn receptor Tyr119) which resultsina loss of ligand binding (39, 40). had no effect with Fn and vWf. However, this peptide did Furthermore, this amino acid substitution in the RGD crossslightly inhibit the adhesion of platelets to Vn (-29%) and linking region resulted in loss of binding of both RGDS and LGGAKQAGDV (40). Also, a monoclonal antibody (AC7) Fg (28%), respectively. Also, G13 did not inhibitthe GRGDSP-sensitive adhesion of resting platelets to Fn even against residues 109-128 of GPIIIa interacted only with stimthough the a-subunitof this Fnreceptor (IC= a6)shares81% ulatedplatelets and inhibitedplatelet aggregation and Fg homology with GPIIb in the region of IIb cross-linked by a binding (41). Interestingly, the binding of AC7 to stimulated carboxyl-terminal y-chain peptide (with only two amino acid platelets was inhibited by Fg and peptides containing the differences relative to G13 (GDGaDLLVGAPL)) (24, 34, sequences RGDF or LGGAKQAGDV (41). Peptides corre35). The basis for this differential effect is unknown; however, sponding to residues 204-229 and 217-231of GPIIIa have plausible explanations include the following: 1) theindividual recently been demonstrated to inhibit the binding of Fg, Fn, amino acid differences in the highly conserved K16 cross- Vn, and vWf to purified GPIIb/IIIa and bind directly to Fg, linking region of the two a-subunits, and/or 2) the presence Fn, andvWf (42,43). In anotherstudy, multiple sequences in of different @-subunits, and/or 3) other regions of the a- the NHz-terminalregion of GPIIIa were implicated as putative fibrinogen binding sites (44). subunits may influence ligand specificity. In sum, these datasuggest the existence of non-contiguous Our previous data implicated residues 309-312 in GPIIbas comprising at least part of a Fg binding site on GPIIb (25). ligand binding sites in both subunitsof GPIIb/IIIa. InterestThis sequence is present in theregion of GPIIb (residues 294- ingly, several earlier studies demonstrated direct interaction 314) found to be cross-linked by the Fg y-chain peptide (24). of RGD peptides to both subunits (20, 21). Furthermore in Subsequently, a peptide corresponding to residues 296-306 of cross-linking studies with both RGD and y-chain peptides, cross-linking could be inhibited by either peptide (21, 24). It has been demonstrated that thebinding of RGD and y-chain T peptides is mutually exclusive and that the sites recognized by these peptides appear to be distinct, yet overlapping (20, 45-47). Evidence obtained with arelated member of the integrin family of receptors, a,& suggests an RGD binding site composed of non-contiguous sequences of the a-subunit and a region from the P-subunit of the Vn receptor (48, 49). A picture seems to be evolving in which a binding pocket, made of several non-contiguous sequences present in both n R.PLTS ADPIEPIN. THROMBIN subunits of GPIIb/IIIa, may form as a result of a conforma8 tional change in the Fg receptor following platelet activation TREATMENTS (41, 48-57). FIG. 5. GPIIb, 300-312(G13) inhibits the adhesion of stimThe question ofhow different amino acid sequences in a ulated platelets, but notresting platelets, to Fn. The percentage of platelets adhered to Fn-coated wells is indicated on the ordinate. single ligand can interact with a common binding cleft may The solid bars (control), represent the adhesion of stimulatedplatelets be explained by recent data obtained with anti-idiotypic an(either ADP/epinephrine or a-thrombin) or resting platelets to Fnin tibodies against the antigen-binding region of PAC-1 (a monothe presence of a scrambled control peptide. The cross-hatched bars clonal antibody which binds to activated (but not resting) correspond to adhesion in the presence of G13.Peptides were at a final concentration of 1.5 mM. These data represent the sum of the GPIIb/IIIa and inhibits Fg binding; Ref. 57). These studies means of six separate pooled experiments. Error bars correspond to suggest that the carboxyl-terminal y-chain region of fibrinogen may exist in a conformation similar to an AaRGDregion the range of adhesion.

-

11733

GPIIb 300-312 Peptide Acts as Common Ligand Binding Site of the molecule (58). If this were the case, it would provide a rationale to explain the inhibition of binding of multiple adhesive RGD ligands to the Fg receptor by short linear peptides (such as G13) which represent a presumptive Fg ychain binding domain of GPIIb/IIIa. Our data demonstrating direct binding of G13 to Vn (an RGD containing ligand which lacks the HHLGGAKQAGDV sequence) are consistent with this hypothesis. While our data do not exclude an effect of the peptide on platelets, our data which directly demonstrate that G13 binds to atleast Fg and Vn and thedistinct inhibition responses of platelet adhesion to the different ligands make this explanation unlikely. Acknowledgments-We thank Dr. David Amrani for the kind gift of peak 1 Fg and the initial batch of the EIIYPAGLV peptide, Dr. John Fenton I1 for the a-thrombin, Dr. Deane Mosher and Steve Bittorf for the vitronectin, Dr. Zaverio Ruggeri for the Von Willebrand factor, and Dr. Dan Walz for the thrombospondin. We especially thank Drs. Charles A. Lessman and David F. Smith for comments concerning the manuscript. We thank Robert Loudon and Jerry Derrick for technical assistance. REFERENCES 1. George, J. N.,Nurden, A. T., and Phillips, D. R. (1984) N. Engl. J. Med. 3 1 1 , 1084-1098 2. Harker, L. A. (1990) in Hematology (Williams, J. W., Beutler, E., Erslev, A. J., and Lichtman, M. A., eds) 4th Ed., pp. 1559-1569, McGraw-Hill, New York 3. Phillips, D. R., Charo, I. F., Parise, L. V., and Fitzgerald, L. A. (1988) Blood 71,831-843 4. Ginsberg, M. H., Loftus, J. C., and Plow, E. F. (1988) Thromb. Haemost. 6 9 , 1-6 5. Bennett, J. S. (1990) Sem. Hematol. 2 7 , 186-204 6. Kieffer, N.. and Phillius. D. R. (1990) Annu. Reu. Cell Biol. 6.. 329-357 7. Bennett, J..S. (1991) Ann. N. Y..Acad. Sci. 614,214-228 8. Ruoslahti, E., and Pierschbacher, M. D. (1987) Science 238,491-497 9. Tamkun, J. W., DeSimone, D. W., Fonda. D.. Patel. R. $3..and Buck. C. (1986) Cell 46,271-282 10. Buck, C., Shea, E., Duggan, K., and Horwitz, A. F. (1986) J. Cell Biol. 1 0 3 , 2421-2428 11. Hynes, R. 0.(1987) Cell 48,549-554 12. Hemler, M. E., Huang, C., and Schwartz, L. (1987) J. Biol. Chem 2 6 2 , 3300-3309 13. Anderson, D. C., and Springer, T. A. (1987) Annu. Reu. Med. 38,175-194 14. Gartner, T.K., and Bennett, J. S. (1985) J. Biol. Chem. 260,11891-11894 15. Plow,E.F., Pierschbacher, M. D., Ruoslahti, E., Marguerie, G., and Ginsberg, M. H.(1985) Proc. Natl. Acad. Sei. U. S. A . 82,8057-8061 16. Haverstick, D. M., Cowan, J. F., Yamada, K. M., and Santoro,S. A. (1985) Blood 66,946-952 17. Ginsberg, M. H., Pierschbacher, M. D., Ruoslahti, E., Marguerie, G., and Plow, E. F. (1985) J. Biol. Chem. 260,3931-3936 18. Thiagarajan, P., andKelly, K. L. (1987) J. Biol. Chem. 263,3035-3038 19. Gardner, J. M., and Hynes, R. 0.(1985) Cell 42,439-448 20. Santoro, S. A., and Lawing, W. J. (1987) Cell 48,867-873 21. D’Souza, S. E., Ginsberg, M. H., Lam, S. C.-T., and Plow, E. F. (1988) J . Biol. Chem. 263,3943-3951 22. Kloczewiak, M., Timmons, S., and Hawiger, J. (1983) Thromb. Res. 2 9 , 249-255 ”

23. 24. 25. 26. 27.

Kloczewiak. M.. Timmons. S.. Lukas. T. J.. and Hawker. Bio- ~J. ,(1984) . ,~ chemist6 23; 1767-1774 ’ D’Souza, S. E., Ginsberg, M. H., Burke, T. A., and Plow, E. F. (1990) J. Biol. Chem. 266.3440-3446 Gartner, T. K., and Taylor, D. B. (1990) Thromb. Res. 6 0 , 291-309 Amrani, D. L., and Kirschbaum, N. E. (1991) Thromb. Haemost. 66,1069a Kirschbaum. N.E.. Mosesson. M. W.. and Amrani. D. L. (1992) Blood. in I

,

~~~

nrew

28. T &%;: D. B., Amrani, D.L., Kirschbaum, N. E., Matsueda, G.L., and Gartner, T. K. (1991) J. Cell Biol. 1 1 6 , 1669a 29. Knutson, V. P. (1988) J. Biol. Chem., 2 6 3 , 14146-14151 30. Gartner, T.K., Bennett, J. S., and Ogilvie, M. L. (1987) Blood 70,351a 31. Gartner, T. K., and Taylor, D. B. (1991) Proc. SOC.Erp. Biol. Med. 198, 649-657 32. Muranog, G., and Bick, R. L. (1980) in Plotelet Disorders (Triplett, D., ed) pp. 101-112, CRC Press, Boca Raton, FL 33. Piotrowicz, R. S., Orchekowski, R. P., Nugent, D. J., Yamada, K. M., and Kunicki, T. J. (1988) J. Cell Biol. 106,1359-1364 34. Poncz, M., Eisman, R., Heidenreich, R., Silver, S. M., Vilaire, G., Surrey, S., Schwartz, E., and,Bennett, J. S.(1987)J. Biol. Chem. 262,8476-8482 35. Argraves, W. S., Suzukl, S., Arai, H., Thompson, K., Pierschbacher, M. D., and Ruoslahti, E. (1987) J. Cell Biol. 106,1183-1190 36. D’Souza, S. E., Ginsberg, M. H., Matsueda, G. R., and Plow, E. F. (1991) Nature 360,66-68 37. Calvete, J. J., Arias, J.,Alvarez,M.V.,Lopez,M. M., Henschen, A,, Gonzalez-Rodriguez,J. (1991) Biochem. J. 273,767-775 38. D’Souza, S. E., Ginsberg, M. H., Burke, T. A., Lam, S. C.-T., and Plow, E. F. (1988) Science 242,91-93 39. Loftus, J. C.,O’Toole, T. E.,Plow, E. F. Glass, A., Frelinger, A. L., Ginsberg, M. H. (1990) Science 249,915-bl8 40. Ginsberg, M. H., Loftus, J. C D’Souza, S. E. O’Toole, T. E., Frelinger, A. L., 111, and Plow, E. F. (19;O) J. Cell Bioehkm. Su 1 14, 1398 41. Andrieux, A., Rabiet, M. J., Chapel, A., Concord, f?,.and Marguerie, G. (1991) J. Biol. Chem. 266,14202-14207 42. Charo, I. F., Nannizzi, L., Phillips, D. R., Hsu, M. A., and Scarborough, R. M. (1991) J. Biol. Chem. 266,1415-1421 43. Cook, J. J., Trybulec, M., Lasz, E.C., Khan, S., and Niewiarowski, S. (1992) Biochrm. B~ophys.Acta 11 19,346-354 44. Calvete, J. J., Arias, J., Alvarez, M. V., Lopez, M. M., Henschen, A., and Gonzalez-Rodriguez,J. (1991) Biochem. J. 274,457-463 45. Lam, S. C.-T., Plow, E. F., Smith, M. A., Andrieux, A., Ryckwaert, J. J., Marguerie, G., and Ginsberg, M. H. (1987) J. Biol. Chem. 262,947-950 46. Bennett, J. S. Shattil, S. S. Power, J. W., and Gartner, T. K. (1988) J. Bwl. Chem. 263,12948-1i593 47. Andrieux, A., Hudry-Clergeon, G., Ryckewaert, J. J., Chapel, A., Ginsberg, M. H., Plow, E. F., and Marguerie, G. (1989) J. Biol. Chem. 264,92589265 48. Smith, J. W., and Cheresh D. A. (1988) J. Biol. Chem. 263, 18726-18731 49. Smith, J. W., and Cheresh: D. A. (1990) J. Biol. Chem. 266,2168- 2172 50. Parise, L. V., Helgerson, L. L., Steiner, B., Nannizzi, L., and Phillips, D. R. (1987) J. Biol. Chem. 262,12597-12602 51. Frelinger A.L., 111, Lam S. C-T. Plow, E. F., Smith, M. A,, Loftus, J. C., and Ginsberg, M. H. (i988) J. Biol. Chem. 263,12397-12402 52. Frelinger, A.L., 111, Cohen I., Plow, E. F., Smith M. A. Roberts, J., Lam, S. C-T., and Ginsberg, M . H. (1990) J. Biol. C&m. 266,6346-6352 53. Kouns, W. C., Wall, C. D., White, M. M., Fox, C. F., and Jennings, L. K. (1990) J. Biol. Chem. 265,20594-20601 54. O’Toole, T. E., Loftus, J. C., Du, X., Glass, A.A. Ruggeri, Z. M. Shattil, S. J., Plow, E. F., and Ginsberg, M. H. (1990) dell Regul. 1,883”893 55. Du, X.,Plow, E. F., Frelin er A.L. I11 O’Toole, T. E., Loftus, J. C., and Ginsberg, M. H. (1991) &li66,4b9-i16 56. Frelinger, A. L., 111, Du, X., Plow, E. F., and Ginsberg, M. H. (1991) J. Biol. Chem. 266,17106-17111 57. Shattil, S. J., Hoxie, J. A., Cunningham, M., and Brass, L. F. (1985) J. Biol. Chem. 260. 11107-11114 58. Abrams, C. S., Ruggeri, 2. M., Taub, R.,Hoxie, J. A., Nagaswami, C., Welsel, J. W., and Shattil, S. J. (1992) J. B~ol.Chem. 2 6 7 , 2775-2785 59. Suzuki, S. Argraves, W. S Arai, H., Languino L.R., Pierschbacher, M. D., Ruohahti, E. (1987) j.Biol. Chem. 262,1b080-14085